Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Tumor Vaccination with CD25-depleted PBMC in Melanoma
NCT00961376Phase 2Terminated
- Start
- Jul 2009
- Primary completion
- Jan 2015
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of autologous regulatory T cell-depleted lymphocytes in melanoma. Started Jul 2009; status: terminated.
02
Drugs
autologous regulatory T cell-depleted lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00961376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00961376.